New immunotherapy is the first to shrink lung, breast and mesothelioma tumors
Some two million cancer patients – including 9/11 first responders – may finally be treatable with a new CAR T drug, new research suggests.
Late stage hard tumors like many breast, lung and mesothelioma patients develop are next to impossible to treat, and many patients die in spite of treatment.
An early-stage clinical trial, presented at the American Association of Cancer Research, of a first-of-its-kind immunotherapy shrunk tumors and cut down cancer in the blood of mesothelioma patients by up to 50 percent.
Remarkably, the Memorial Sloan Kettering researchers started seeing improvement in their otherwise treatment resistant patients after a single dose of the treatment.
The researchers identified and tackled several of the flaws in immunotherapy for solid tumors in one go.